Jeffrey D. Helterbrand

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

Gordon R. Bernard, Jean‐Louis Vincent, Pierre‐François Laterre et al. · New England Journal of Medicine · 2001 · 6.1K citations · Full text

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

E. Wesley Ely, Pierre‐François Laterre, Derek C. Angus et al. · Critical Care Medicine · 2003 · 282 citations

Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis

S. Betty Yan, Jeffrey D. Helterbrand, Daniel Hartman et al. · CHEST Journal · 2001 · 257 citations

Inflammation, Severe Sepsis, Poor Outcome +7

The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)

GR Bernard, SP LaRosa, Pierre‐François Laterre et al. · Digital Access to Libraries · 2001 · 213 citations

Inflammation, Translational Medicine, Severe Sepsis +10

Design and methods of the Raloxifene Use for The Heart (RUTH) study

Lori Mosca, Elizabeth Barrett‐Connor, Nanette K. Wenger et al. · The American Journal of Cardiology · 2001 · 166 citations

Heart Failure, Raloxifene Use, Cardiovascular Disease +7